Measuring Quality of Life in Deprescribing Trials: A Scoping Review

Wade Thompson,Carina Lundby, Adam Bleik, Harman Waring, Jung Ah Hong, Chris Xi, Carmel Hughes,Douglas M. Salzwedel,Emily G. McDonald, Jennifer Pruskowski,Sion Scott, Anne Spinewine,Jean S. Kutner,Trine Graabæk, Shahrzad Elmi,Frank Moriarty

Drugs & Aging(2024)

引用 0|浏览3
暂无评分
摘要
Quality of life (QoL) is an important outcome to capture in clinical trials evaluating deprescribing interventions. We aimed to conduct a scoping review to examine how QoL has been measured in deprescribing trials among older people and identify potentially relevant QoL scales, to better inform QoL measurement in future deprescribing trials. We searched MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials, Google Scholar, Epistemonikos, ClinicalTrials.gov, and reference lists of eligible studies (from inception to October 2023). We included randomized and non-randomized comparative studies with a control group that evaluated deprescribing and polypharmacy reduction interventions in people ≥ 65 years of age and measured QoL as an outcome. We also included studies describing the development and validation of QoL scales related to deprescribing, polypharmacy, or medication burden in adults ≥ 18 years of age. Two independent reviewers screened titles and abstracts, then full texts. Two independent reviewers extracted data from 25
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要